A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A phase 2 trial of Daraxonrasib, Nivolumab, Temozolomide, PM8002, Pemetrexed and Carboplatin in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) is a phase 2 interventional study registered as NCT07492680 by Bristol-Myers Squibb, with 260 participants planned, started 2026-07-27 and due to reach its primary completion in 2028-08-15. Interventions recorded: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig and Pemetrexed.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Carboplatin and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialA Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Shares PM8002, Temozolomide, Bristol Myers Squibb and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Shares PM8002, Bristol Myers Squibb, Carboplatin and the tag pipeline.